GlaxoSmithKline, the pharmaceuticals group, said it would transfer a series of medicines and manufacturing assets to Aspen Pharmacare in an innovative £273m deal that gives it 16 per cent of the South African generic drugmaker.

The operation marks a fresh expansion of GSK into both emerging markets and the generics sector, providing protection from slowing growth in developed markets and uncertain income from patented drugs.